We are live on
!
Find out more
QEI
QSV Equity Investors Portfolio holdings
AUM
$67.6M
1-Year Est. Return
0.29%
This Fund
S&P 500
This Quarter
Est. Return
+0.08%
1 Year Est. Return
-0.29%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96M
AUM Growth
-$645K
(-0.67%)
Cap. Flow
+$333K
Cap. Flow
% of AUM
0.35%
Top 10 Holdings %
Top 10 Hldgs %
22.57%
Holding
95
New
8
Increased
17
Reduced
52
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$1.38M |
| 2 |
Cabot Corp
CBT
|
+$1.23M |
| 3 |
Gentex
GNTX
|
+$1.19M |
| 4 |
Quaker Houghton
KWR
|
+$1.16M |
| 5 |
Tennant Co
TNC
|
+$1.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medpace
MEDP
|
+$1.72M |
| 2 |
Insperity
NSP
|
+$1.6M |
| 3 |
Core Laboratories
CLB
|
+$1.33M |
| 4 |
Hawkins
HWKN
|
+$1.32M |
| 5 |
Simulations Plus
SLP
|
+$1.29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.66% |
| 2 | Technology | 17.96% |
| 3 | Industrials | 13.07% |
| 4 | Healthcare | 11.68% |
| 5 | Real Estate | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
EastGroup Properties
EGP
$10.8B
| $279K | 0.29% |
1,669
+8
| +0.5% | +$1.33K |
|
77
Match Group
MTCH
$8.45B
| $279K | 0.29% |
9,026
| – | – |
|
78
Amdocs
DOX
$6.1B
| $278K | 0.29% |
3,050
-3
| -0.1% | -$268 |
|
79
Booz Allen Hamilton
BAH
$9.45B
| $259K | 0.27% |
2,490
+11
| +0.4% | +$1.23K |
|
80
Mine Safety
MSA
$7.45B
| $257K | 0.27% |
1,532
+16
| +1% | +$2.5K |
|
81
Alexandria Real Estate Equities
ARE
$8.28B
| $252K | 0.26% |
3,470
| – | – |
|
82
Chemed
CHE
$7.02B
| $248K | 0.26% |
510
+2
| +0.4% | +$1.14K |
|
83
Halliburton
HAL
$28.2B
| $243K | 0.25% |
11,942
+1,696
| +17% | +$35.6K |
|
84
West Pharmaceutical
WST
$24.7B
| $239K | 0.25% |
1,091
| – | – |
|
85
Campbell Soup
CPB
$6.78B
| $232K | 0.24% |
7,560
+568
| +8% | +$20K |
|
86
Nasdaq
NDAQ
$53.1B
| $227K | 0.24% |
+2,537
| New | +$203K |
|
87
Factset
FDS
$10.1B
| $225K | 0.23% |
+504
| New | +$221K |
|
88
Icon
ICLR
$12.8B
| $212K | 0.22% |
1,459
-7
| -0.5% | -$993 |
|
89
Nuveen Floating Rate Income Fund
JFR
$1.26B
| $140K | 0.15% |
16,576
| – | – |
|
|
EHI
90
Western Asset Global High Income Fund
EHI
$178M
| $76.8K | 0.08% |
11,744
| – | – |
|
|
91
Core Laboratories
CLB
$570M
| – | – |
-88,455
| Closed | -$1.33M |
|
|
92
Hawkins
HWKN
$2.71B
| – | – |
-12,426
| Closed | -$1.32M |
|
|
93
Medpace
MEDP
$16.9B
| – | – |
-5,641
| Closed | -$1.72M |
|
|
94
Insperity
NSP
$1.94B
| – | – |
-17,902
| Closed | -$1.6M |
|
|
95
Simulations Plus
SLP
$370M
| – | – |
-52,468
| Closed | -$1.29M |
|
Similar funds
BBW
YCM
RWA
KWM
IA
MCL
RRCP
BCPEMI
QSV Equity Investors's Q2 2025 Portfolio in Review
As of Q2 2025, QSV Equity Investors held 95 positions worth $96M, down 0.67% from $96.6M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
QSV Equity Investors's Q2 2025 filing shows 8 new, 17 increased, 52 reduced and 5 closed positions. Its largest new stake was Haemonetics: 20,790 shares worth $1.55M. The largest sale was Medpace, an estimated $1.72M.
By sector, the portfolio is most concentrated in Financials at 26% of assets, up from 26% a quarter earlier, followed by Technology and Industrials.
- QSV Equity Investors's largest Q2 2025 buy was Haemonetics: 20,790 shares worth $1.55M.
- QSV Equity Investors added most to Gentex in Q2 2025, an estimated $1.19M increase.
- QSV Equity Investors's biggest Q2 2025 reduction was Catalyst Pharmaceutical, cutting an estimated $718K.
- QSV Equity Investors fully exited Medpace in Q2 2025, selling an estimated $1.72M.
- QSV Equity Investors's ten largest holdings make up 23% of its $96M portfolio in Q2 2025.
- QSV Equity Investors opened 8 new positions and closed 5 in Q2 2025.
- QSV Equity Investors's portfolio value fell 0.67% quarter-over-quarter to $96M.
Based on QSV Equity Investors's 13F filing for Q2 2025, filed 13 Aug 2025.